Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Y Hua

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|July 2, 2014
Multiplicity adjustments in testing for bioequivalenceSteven Y Hua, Siyan Xu, Ralph B D'Agostino
Statistics in Medicine|January 10, 2014
Inference of bioequivalence for log-normal distributed data with unspecified variancesSiyan Xu, Steven Y Hua, Ronald Menton, et al.
Expert Review of Clinical Immunology|March 6, 2018
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01)Ramesh Palaparthy, Chandrasekhar Udata, Steven Y Hua, et al.
Investigational New Drugs|March 20, 2019
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumorsLee S Rosen, Robert Wesolowski, Raffaele Baffa, et al.
Arthritis Research & Therapy|August 17, 2018
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisRoy M Fleischmann, Rieke Alten, Margarita Pileckyte, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
Ophthalmology|June 10, 2008
Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Martin Kaback, Stephen V Scoper, George Arzeno, et al.
Investigational New Drugs|January 16, 2018
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumorsGentry T King, Keith D Eaton, Brandon R Beagle, et al.
Arthritis Research & Therapy|July 29, 2018
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapyStanley B Cohen, Rieke Alten, Hideto Kameda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 25, 2020
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic EsophagitisEvan S Dellon, Margaret H Collins, Marc E Rothenberg, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|July 2, 2014
Multiplicity adjustments in testing for bioequivalenceSteven Y Hua, Siyan Xu, Ralph B D'Agostino
Statistics in Medicine|January 10, 2014
Inference of bioequivalence for log-normal distributed data with unspecified variancesSiyan Xu, Steven Y Hua, Ronald Menton, et al.
Expert Review of Clinical Immunology|March 6, 2018
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01)Ramesh Palaparthy, Chandrasekhar Udata, Steven Y Hua, et al.
Investigational New Drugs|March 20, 2019
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumorsLee S Rosen, Robert Wesolowski, Raffaele Baffa, et al.
Arthritis Research & Therapy|August 17, 2018
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisRoy M Fleischmann, Rieke Alten, Margarita Pileckyte, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
Ophthalmology|June 10, 2008
Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Martin Kaback, Stephen V Scoper, George Arzeno, et al.
Investigational New Drugs|January 16, 2018
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumorsGentry T King, Keith D Eaton, Brandon R Beagle, et al.
Arthritis Research & Therapy|July 29, 2018
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapyStanley B Cohen, Rieke Alten, Hideto Kameda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 25, 2020
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic EsophagitisEvan S Dellon, Margaret H Collins, Marc E Rothenberg, et al.
Pageof 2